Physician profile
Thomas Glass
NPI 1992701833
$6,759.21
in general payments reported to CMS, 2019-2025
28 companies · $1,823 in 2025
The $1,823 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $159 · 2021: $378 · 2022: $956 · 2023: $1,423 · 2024: $1,364 · 2025: $1,823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,530 · Education: $79.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,530.04 |
| Education | $79.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,173.97 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $935.98 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $780.44 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $650.00 | 2022-2025 | |
| Kaleo, INC. | $447.48 | 2019-2024 | Auvi-Q |
| Csl Behring | $435.97 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Pfizer INC. | $407.77 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $356.08 | 2019-2023 | Airduo Digihaler |
| Novartis Pharmaceuticals Corporation | $236.70 | 2019-2025 | |
| Optinose US, INC. | $201.98 | 2019-2024 | |
| Amgen INC. | $198.78 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $187.73 | 2019-2024 | Xolair |
| Grifols USA, LLC | $128.71 | 2023-2025 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $122.91 | 2025 | Neffy |
| Octapharma USA, INC. | $104.60 | 2023-2024 | Cutaquig, Panzyga |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $100.78 | 2024-2025 | Ayvakit |
| Azurity Pharmaceuticals, INC. | $41.39 | 2025 | Alvesco |
| Lilly USA, LLC | $40.03 | 2025 | Ebglyss |
| Merck Sharp & Dohme LLC | $35.00 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.12 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.62 | 2025 | Cuvitru |
| Biocryst US Sales Co., LLC | $24.10 | 2025 | Orladeyo |
| Verona Pharma, INC. | $23.19 | 2025 | Ohtuvayre |
| Circassia INC. | $17.76 | 2019 | |
| Hikma Pharmaceuticals USA | $17.53 | 2023 | Ryaltris |
| Galderma Laboratories, L.P. | $14.00 | 2025 | Nemluvio |
| Alk-Abello, INC | $12.34 | 2022 | |
| Incyte Corporation | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Glass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.